On February 22, 2012, an Australian ethics committee rejected the protocol for our planned Australian study of MDMA-assisted psychotherapy for PTSD. The committee raised issues relating to study design that MAPS and the Australian research team believe can be successfully addressed, and that in some cases represented misunderstandings on the part of the reviewers. MAPS and the Australian psychedelic research group Psychedelic Research in Science and Medicine (PRISM) are now preparing a reply. We are hopeful that a version of the protocol can eventually be approved.
